Chimeric Therapeutics Limited: Company Profile

Background

Overview

Chimeric Therapeutics Limited is an Australian clinical-stage cell therapy company established in 2020, dedicated to developing and commercialising innovative cell therapies for oncology. The company focuses on harnessing the immune system to target and eliminate cancer cells, aiming to provide transformative treatments for patients with advanced cancers.

Mission and Vision

Chimeric's mission is to develop and commercialise novel cell therapies for cancer patients, striving to create a better future for those affected by cancer. Their vision is a world where all patients with advanced cancer receive transformative therapies.

Primary Area of Focus

The company's primary focus is on cell-based immunotherapies, specifically Chimeric Antigen Receptor T-cell (CAR T) and Natural Killer (NK) cell therapies, targeting various solid tumors. Chimeric is the only clinical-stage cell therapy biotechnology company in Australia, positioning itself as a leader in this field.

Industry Significance

As a pioneer in cell therapy, Chimeric Therapeutics contributes significantly to the biotechnology sector, particularly in the development of advanced cancer treatments. The company's innovative approach addresses the unmet needs in oncology, offering potential curative options for patients with solid tumors.

Key Strategic Focus

Core Objectives

Chimeric Therapeutics aims to discover, develop, and commercialise novel cell therapies with the highest potential for patients, focusing on delivering results for patients, partners, and investors.

Specific Areas of Specialisation

The company specialises in:

Autologous CAR T Cell Therapies: Utilising a patient's own T cells to create personalised treatments.

Allogeneic NK Cell Therapies: Employing NK cells from healthy donors to develop off-the-shelf therapies.

Key Technologies Utilised

Chimeric leverages advanced cell therapy technologies, including:

CDH17 CAR T Therapy: A first-in-class autologous CAR T therapy targeting CDH17, developed at the City of Hope Cancer Centre.

CLTX CAR T Therapy: A novel CAR T therapy incorporating chlorotoxin (CLTX), derived from scorpion venom, to target glioblastoma and other solid tumors.

CORE-NK Platform: An allogeneic NK cell platform designed for the treatment of various cancers.

Primary Markets or Conditions Targeted

Chimeric focuses on treating solid tumors, including:

Colorectal Cancer

Gastric Cancer

Intestinal Neuroendocrine Tumors

Glioblastoma

Other MMP2-Expressing Solid Tumors

The company is actively developing therapies for these conditions through its clinical trials.

Financials and Funding

Funding History

Chimeric Therapeutics has raised a total of approximately AUD 39.3 million through capital raisings prior to its public listing on the Australian Securities Exchange (ASX) in January 2021.

Recent Funding Rounds

In October 2025, Chimeric completed a follow-on equity offering raising AUD 6.6 million, followed by another offering in December 2025 raising AUD 4.4 million.

Notable Investors

Specific details about individual investors are not publicly disclosed.

Intended Utilisation of Capital

The funds raised are intended to support the advancement of Chimeric's clinical trials, further development of its cell therapy pipeline, and expansion of its operational capabilities.

Pipeline Development

Key Pipeline Candidates

1. CDH17 CAR T Therapy (CHM 1101): A first-in-class autologous CAR T therapy targeting CDH17, currently in Phase 1/2 clinical trials for advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors.

2. CLTX CAR T Therapy (CHM 1101): A novel CAR T therapy incorporating chlorotoxin (CLTX) for targeting glioblastoma and other solid tumors, in Phase 1 clinical trials.

3. CORE-NK Platform (CHM 0201): An allogeneic NK cell therapy platform, with two Phase 1b trials initiated for the treatment of acute myeloid leukemia, colorectal cancer, and other solid tumors.

Stages of Clinical Trials or Product Development

CDH17 CAR T Therapy: Phase 1/2 clinical trials.

CLTX CAR T Therapy: Phase 1 clinical trials.

CORE-NK Platform: Phase 1b clinical trials.

Target Conditions

The therapies target various solid tumors, including colorectal cancer, gastric cancer, intestinal neuroendocrine tumors, glioblastoma, and other MMP2-expressing solid tumors.

Relevant Timelines for Anticipated Milestones

Specific timelines for upcoming milestones are not publicly disclosed.

Technological Platform and Innovation

Proprietary Technologies

CDH17 CAR T Therapy: Targets CDH17, a biomarker associated with poor prognosis in certain cancers.

CLTX CAR T Therapy: Utilises chlorotoxin (CLTX) derived from scorpion venom to target glioblastoma and other solid tumors.

CORE-NK Platform: An allogeneic NK cell platform designed for the treatment of various cancers.

Significant Scientific Methods

CAR T Cell Therapy: Engineering a patient's own T cells to attack cancer cells.

NK Cell Therapy: Utilising NK cells from healthy donors to develop off-the-shelf therapies.

AI-Driven Capabilities

While Chimeric Therapeutics employs advanced technologies in its research and development processes, specific details about AI-driven capabilities are not publicly disclosed.

Leadership Team

Key Executive Profiles

Dr. Rebecca McQualter: Chief Executive Officer with extensive experience in biotechnology and cell therapy, leading Chimeric's strategic direction and operations.

Dr. Stephanie H. Astrow: Chief Scientific Officer with a strong background in scientific research, overseeing the development of Chimeric's cell therapy pipeline.

Mr. Phillip Hains: Chief Financial Officer and Joint Company Secretary with expertise in financial management, responsible for Chimeric's financial strategy and operations.

Mr. Nathan Jong: Joint Company Secretary, assisting in corporate governance and compliance matters.

Leadership Changes

In November 2025, Chimeric appointed Dr. Brad Glover as Non-Executive Director and Chair, bringing over 20 years of leadership experience in global biopharmaceuticals and cell therapy. Phillip Hains retired as CFO and Joint Company Secretary but continues as a Non-Executive Director.

Competitor Profile

Market Insights and Dynamics

The cell therapy market, particularly CAR T and NK cell therapies for solid tumors, is rapidly growing, with the CAR-T cell therapy market projected to reach a value of around $6.1 billion by 2030.

Competitor Analysis

Chimeric Therapeutics faces competition from various companies in the cell therapy and oncology sectors, including: